ArticlePharmacoEconomics - open2022

Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067.

Timothy Baker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.